Product nameAnti-Bcl-2 (phospho S70) antibody
See all Bcl-2 primary antibodies
DescriptionRabbit polyclonal to Bcl-2 (phospho S70)
Specificityab28819 recognises Phospho-BCL-2(Ser70).
Tested applicationsSuitable for: WB, ELISA, IP, IHC-P, Flow Cytmore details
Species reactivityReacts with: Human
Synthetic peptide corresponding to Human Bcl-2.
Database link: P10415
- Breast carcinoma
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol, 0.87% Sodium chloride
Without Mg2+ and Ca2+
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab28819 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Our Abpromise guarantee covers the use of ab28819 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Predicted molecular weight: 26 kDa.|
|IP||Use at an assay dependent concentration.|
|IHC-P||1/50 - 1/100.|
|Flow Cyt||Use at an assay dependent concentration. PubMed: 19738029
ab171870 - Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody.
FunctionSuppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785).
Tissue specificityExpressed in a variety of tissues.
Involvement in diseaseA chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.
Sequence similaritiesBelongs to the Bcl-2 family.
DomainBH1 and BH2 domains are required for the interaction with BAX and for anti-apoptotic activity.
The BH4 motif is required for anti-apoptotic activity and for interaction with RAF1 and EGLN3.
The loop between motifs BH4 and BH3 is required for the interaction with NLRP1.
modificationsPhosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation on Ser-70 by PKC is required for the anti-apoptosis activity and occurs during the G2/M phase of the cell cycle. In the absence of growth factors, BCL2 appears to be phosphorylated by other protein kinases such as ERKs and stress-activated kinases. Phosphorylated by MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulates starvation-induced autophagy. Dephosphorylated by protein phosphatase 2A (PP2A).
Proteolytically cleaved by caspases during apoptosis. The cleaved protein, lacking the BH4 motif, has pro-apoptotic activity, causes the release of cytochrome c into the cytosol promoting further caspase activity.
Monoubiquitinated by PARK2, leading to increase its stability. Ubiquitinated by SCF(FBXO10), leading to its degradation by the proteasome.
Cellular localizationMitochondrion outer membrane. Nucleus membrane. Endoplasmic reticulum membrane.
- Information by UniProt
- Apoptosis regulator Bcl 2 antibody
- Apoptosis regulator Bcl-2 antibody
- Apoptosis regulator Bcl2 antibody
Western blot analysis of lysates from HeLa cells treated with LPS (40nM, 30mins), K562 cells treated with calyculin A (50ng/ml, 30mins) and COS-7 cells treated with H2O2 (1ng/ml, 15mins), using BCL-2 (Phospho-Ser70) Antibody. The lane on the right is blocked with the phospho peptide.
Immunohistochemical analysis of paraffin-embedded breast carcinoma, using anti-Phospho-BCL2(Ser70) antibody (ab28819). Left: Untreated; Right: Treated with synthesized phosphopeptide.
This product has been referenced in:
- Fan L et al. Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells. Oncotarget 8:29823-29832 (2017). IHC . Read more (PubMed: 28415735) »
- Kendrick SL et al. BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Hum Pathol 45:2144-53 (2014). Read more (PubMed: 25090918) »